Australian immunotherapy company Immutep has secured fast-track designation from the US FDA for its eftilagimod alpha for use in combination with MSD's KEYTRUDA (pembrolizumab). …
Second fast-track designation for Australian immunotherapy company
October 6, 2022 Latest NewsBioPharmaAustralian Biotech
Latest Video
New Stories
-
Pharmac announces plan to update access and supply of COVID-19 treatments
August 12, 2025 - - Latest News -
If the cost of this process is truly rising at this rate, then the process must be the problem
August 12, 2025 - - Latest News -
Biogen announces leadership transition for Australia and New Zealand
August 12, 2025 - - Latest News -
Syntara receives FDA guidance for amsulostat in myelofibrosis treatment
August 11, 2025 - - Australian Biotech -
Noxopharm advances HERACLES trial for novel autoimmune disease drug
August 11, 2025 - - Australian Biotech -
Could the realities of AI quickly date or even swamp the HTA Review outcomes?
August 11, 2025 - - Latest News -
We asked ChatGPT to produce a podcast script explaining the pros and cons of the HTA Review
August 10, 2025 - - Latest News